Daily Brief Thematic (Sector/Industry): Thematic Report: Indian Paper Industry- Low Margin and more

In today’s briefing:

Thematic Report: Indian Paper Industry- Low Margin, China Dumping, Capex
Rio Tinto’s Green Aluminium Bet on India: A Strategic Pivot Amid Global Decarbonization
APAC Healthcare Weekly (April 20)- Neuren, Chugai, Eisai, Telix, Biocon, Aurobindo Pharma

Thematic Report: Indian Paper Industry- Low Margin, China Dumping, Capex

The paper industry is poised for gradual recovery by FY26, driven by strategic product diversification, integration, and acquisitions, with high-margin segments like tissue and packaging leading the way.
Despite cautious capex, companies focusing on inorganic growth and regional access via acquisitions, like ITC’s Century Pulp deal, will enhance market positioning.
As plantations mature, and anti-dumping measures take effect, the industry could stabilize by FY26, with integrated players gaining faster margin recovery.

Rio’s Entry: Rio Tinto plans a $5–7B green aluminium project in India with AMG M&M, targeting 1 Mtpa smelting and 2 Mtpa refining powered by renewables.
Why India: Aluminium demand is rising; India offers bauxite, coal, caustic, and strong domestic growth—ideal for scaling low-carbon aluminium production.
Risks & Signals: Land issues remain a risk, but ArcelorMittal’s success shows improved project viability; Rio bets on aluminium’s green future and circular economy edge.

FDA has confirmed the primary endpoints for Neuren Pharmaceuticals’ planned Phase 3 pivotal clinical trial of NNZ-2591 in Phelan-McDermid syndrome. Eisai has ultimately received its long-waited European approval for Leqembi.
Chugai Pharmaceutical’s outlicensed oral GLP-1 drug candidate orforglipron has shown positive topline Phase 3 results. Telix announced preliminary results from the Phase 2 study of TLX101 in recurrent high-grade glioma.
Biocon secured market entry date for Yesafili, an interchangeable biosimilar to Eylea in the U.S. FDA has issued Form 483 with 11 observations for Aurobindo Pharma’s North Carolina inhaler plant.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network